Latest Atypical antipsychotics Stories
93% of patients treated with INVEGA TRINZA(TM) remained relapse-free at the end of long-term maintenance trial TITUSVILLE, N.J., May 19, 2015 /PRNewswire/ -- There's a new treatment option
TITUSVILLE, N.J., May 11, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today that the U.S.
Braeburn acquires six-month risperidone implant from Endo Pharmaceuticals; Phase 3 clinical trial planned for 2015 PRINCETON, N.J., May 1, 2015 /PRNewswire/ -- Braeburn Pharmaceuticals
Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study
DeepResearchReports.com adds "Global and China Olanzapine Industry 2015 Research Report" , "2015 Global Quetiapine Fumarate Industry Report" and "Global Montelukast Sodium Industry 2015 - 2020" Research
CORAL SPRINGS, Florida, April 9, 2015 /PRNewswire/ -- According to a recent article [http://blogs.wsj.com/pharmalot/2014/09/29/high-prices-for-orphan-drug-can-be-sustained-a-payer-survey-shows
Results served as basis for regulatory filing with U.S.
- First atypical antipsychotic to be approved for pediatric patients with bipolar I disorder in the last five years - DUBLIN, March 13, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced
TITUSVILLE, N.J., Jan. 19, 2015 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S.
The study’s publication comes as hundreds of people pursue Risperdal lawsuits for complications allegedly associated with the drug, including gynecomastia (male breast growth). New
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.